uk: Consultation on draft menopause guideline

Consultation on draft menopause guideline NICE (Monday 1 June) opened a public consultation on a draft clinical guideline about diagnosis and management of menopause. Menopause is when a woman stops having menstrual periods as she is reaching the end of her natural reproductive life. The drop in the level of oestrogen, the sex hormone, can…

Read More

uk: New drug availability

Various chronic diseases New drugs available on the NHS for chronic lymphocytic leukaemia. NICE has issued two pieces of final guidance recommending obinutuzumab …. more (Gazyvaro, Roche) and ofatumumab .…more (Arzerra, Novartis), which are each given in combination with chlorambucil, for people with previously untreated chronic lymphocytic leukaemia if treatments containing fludarabine or bendamustine are…

Read More

ie: Review on health effects of community water fluoridation

HRB publishes review on health effects of community water fluoridation No definitive evidence that community water fluoridation has negative health effects. The Health Research Board(HRB) published an in-depth evidence review of existing research in relation to the health effects of community water fluoridation. The HRB has found no definitive evidence that community water fluoridation is…

Read More

uk: Two eye treatments for serious diabetic eye conditions

Two eye treatments for serious diabetic eye condition – final draft guidance NICE recommended aflibercept solution for injection (Eylea, Bayer Pharma), and dexamethasone intravitreal(i) implant (Ozurdex, Allergan) as possible treatment options for some people with diabetic macular oedema, in two separate pieces of final draft guidance published (2 June). This oedema is a common complication…

Read More
efsa logo

eu: Endocrine disruptors, identification and related impacts

Event European Food Safety Authority (EFSA) Conference – “Endocrine disruptors: criteria for identification and related impacts”, 1 June 2015, Brussels The conference will inform Member States, Members of the European Parliament, third country representatives and stakeholders about the on-going impact assessment on criteria to identify endocrine disruptors and to provide a platform for further exchanges…

Read More

uk: Consultation on treatments for spinal arthritis

Consultation on draft guidance recommending treatments for types of arthritis that affecting spine NICE has today published draft guidance on adalimumab (Humira, AbbVie), etanercept (Enbrel, Pfizer), infliximab (Remicade, Merck Sharp & Dohme; Inflectra, Hospira; Remsima, Celltrion), certolizumab pegol (Cimzia, UCB Pharma) and golimumab (Simponi, Merck Sharp & Dohme) – known as TNF-alpha inhibitors – for…

Read More